Detalhe da pesquisa
1.
IL-15/IL-15Rα-Fc fusion protein XmAb24306 potentiates activity of CD3 bispecific antibodies through enhancing T cell expansion.
Mol Cancer Ther
; 2024 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38739434
2.
IMiDs Augment CD3-Bispecific Antibody-Induced CD8+ T-Cell Cytotoxicity and Expansion by Enhancing IL2 Production.
Mol Cancer Ther
; 22(5): 659-666, 2023 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36822576
3.
Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian Cancer.
Mol Cancer Ther
; 20(4): 716-725, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33536191
4.
Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody.
JCI Insight
; 5(7)2020 04 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32271166
5.
CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity.
Sci Transl Med
; 11(508)2019 09 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31484792
6.
Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma.
J Med Chem
; 62(4): 2140-2153, 2019 02 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-30715878
7.
Relative Target Affinities of T-Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model.
Mol Cancer Ther
; 17(4): 776-785, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29339550
8.
Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3.
Sci Transl Med
; 10(463)2018 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-30333240
9.
Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells.
MAbs
; 9(2): 213-230, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-27929752
10.
Discovery of 5-Azaindazole (GNE-955) as a Potent Pan-Pim Inhibitor with Optimized Bioavailability.
J Med Chem
; 60(10): 4458-4473, 2017 05 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-28445037
11.
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing.
Cancer Cell
; 31(3): 383-395, 2017 03 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28262555
12.
FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma.
Mol Cancer Ther
; 11(10): 2222-32, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22807577
13.
Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.
Blood
; 110(2): 616-23, 2007 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17374736